NY-DAVIS-POLK
17.1.2023 16:34:38 CET | Business Wire | Press release
Davis Polk today announced that the firm is launching a European antitrust practice in Brussels. The practice will be led by Jürgen Schindler and Frances Dethmers.
“The European Commission is a critical antitrust authority. We are excited to be able to offer our clients sophisticated antitrust capabilities with respect to matters under EU law,” said Neil Barr, Davis Polk’s Managing Partner. “We are thrilled to welcome Jürgen and Frances to Davis Polk.”
The firm’s office in Brussels will open in 2023.
Mr. Schindler and Ms. Dethmers join the firm from Allen & Overy, where both served as partners and Mr. Schindler as co-head of the global competition and antitrust group. Mr. Schindler has extensive experience advising clients on complex international, EU and German merger control, cartel and abuse of dominance cases. His practice encompasses a broad range of sectors, including energy, finance, technology, transport (shipping and airlines), raw materials, chemicals, pharmaceuticals, and consumer and industrial products. In addition, Mr. Schindler litigates before the European courts in Luxembourg.
Mr. Schindler’s practice has extensive geographic coverage; he has advised clients in Europe, the United States, Latin America, Asia and the Middle East. He is admitted to practice in Germany, Belgium and New York. He will join Davis Polk as a partner.
He is a Non-Governmental Adviser to the European Commission and to the German Competition Authority at the International Competition Network (ICN), which includes around 140 competition authorities worldwide, and he regularly contributes to the ICN’s cartel and merger working groups. In addition, he is a long-time editorial board member of the ABA’s Antitrust Magazine Online.
Ms. Dethmers’ practice focuses on international, EU and Dutch competition law. She is an economist and a qualified lawyer. She has extensive experience advising clients from a wide range of industries (in particular, pharmaceuticals, health and life sciences, consumer and industrial products, chemicals and packaging) on highly complex merger control procedures, as well as on cartel investigations, abuse of dominance investigations, intellectual property issues and licensing and distribution agreements. Prior to working in private practice, she worked at the Dutch Competition Authority and the European Commission. Her background as an economist gives her unique insight into the economic concepts and analytical tools at the heart of competition law. She is admitted to practice in the Netherlands. She will join Davis Polk as Special Adviser – EU Antitrust.
“Jürgen and Frances are exceptional lawyers with an outstanding reputation in Brussels, and we are thrilled to have them on board to help us launch our EU antitrust practice,” said Art Burke, head of Davis Polk’s Antitrust & Competition practice. “Their significant experience across merger control matters, cartels and antitrust litigation will benefit our clients greatly and will further solidify our position as a leading global antitrust firm.”
Davis Polk is recognized as a preeminent firm in antitrust and competition law, including with top-tier rankings from publications such as Global Competition Review, Benchmark Litigation and Chambers USA. Clients rely on Davis Polk’s deep experience across the full spectrum of antitrust and competition matters. The firm steers clients through sensitive antitrust investigations and high-stakes litigation, including class actions and government enforcement actions. Davis Polk also serves in a lead role for large defense groups, including in cases alleging cartel behavior in numerous industries and financial markets. Having addressed and resolved antitrust issues presented by thousands of transactions across all economic sectors, the firm is widely recognized in particular for its work on cross-border combinations and routinely acts as coordinating counsel for international merger control review for complex transactions.
Mr. Schindler said, “Frances and I are very excited to be joining Davis Polk, a firm we have long held in high esteem. We have been struck by the strong culture that permeates throughout the firm, and we very much look forward to working with this fantastic team and helping the firm to execute on this strategic expansion of its global antitrust capabilities. We are very grateful for our time as partners at Allen & Overy.”
Ranked as a leading EU competition lawyer by Chambers Europe, Mr. Schindler in 1999 graduated from the University of Hamburg and earned an LLM in European Law from the College of Europe in Bruges. In 2007, he earned an LLM from Georgetown University Law Center focusing on U.S. antitrust law and economics. Ms. Dethmers earned a master’s degree in economics in 1998 and a master’s degree in law in 2001, both from the University of Amsterdam.
About Davis Polk.
Davis Polk & Wardwell LLP (including its associated entities) is an elite global law firm with world-class practices across the board. Clients know they can rely on us for their most challenging legal and business matters. From offices in the world’s key financial centers and political capitals, our more than 1,000 lawyers collaborate seamlessly to deliver exceptional service, sophisticated advice and creative, practical solutions. Visit davispolk.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005803/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
